In this issue, evidence suggests that a Mediterranean diet may have a protective role against MS, the AFFINITY study reports negative findings for opicinumab, and an analysis of data from the MSBase registry suggests that switching to an anti-CD20 drug may be the best strategy for people who relapse on natalizumab.
Also in this issue, a UK study provides valuable insights for clinicians managing patients with MS, and investigators in Iran look at the potential benefit of caffeine for MS-related fatigue.
Download PDF copy of Neurology Research Review – Issue 93